Cargando…

Preparation and Sustained-Release Property of Triblock Copolymer/Calcium Phosphate Nanocomposite as Nanocarrier for Hydrophobic Drug

The P123/ACP nanocomposite with sizes less than 100 nm consisting of triblock copolymer P123 and amorphous calcium phosphate (ACP) has been prepared by using an aqueous solution containing CaCl(2), (NH(4))(3)PO(4), and P123 at room temperature. The P123/ACP nanocomposite is used as the nanocarrier f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Shao-Wen, Zhu, Ying-Jie, Wu, Jin, Wang, Ke-Wei, Tang, Qi-Li
Formato: Texto
Lenguaje:English
Publicado: Springer 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893746/
https://www.ncbi.nlm.nih.gov/pubmed/20671783
http://dx.doi.org/10.1007/s11671-010-9558-5
Descripción
Sumario:The P123/ACP nanocomposite with sizes less than 100 nm consisting of triblock copolymer P123 and amorphous calcium phosphate (ACP) has been prepared by using an aqueous solution containing CaCl(2), (NH(4))(3)PO(4), and P123 at room temperature. The P123/ACP nanocomposite is used as the nanocarrier for hydrophobic drug ibuprofen, based on the combined advantages of both amphiphilic block copolymer and calcium phosphate delivery system. The P123/ACP nanocomposite has a much higher ibuprofen loading capacity (148 mg/g) than the single-phase calcium phosphate nanostructures. The drug release percentage of the P123/ACP nanocomposite in simulated body fluid reaches about 100% in a period of 156 h, which is much slower than that of single-phase calcium phosphate nanostructures. It is expected that the P123/ACP nanocomposite is promising for the application in the controlled delivery of hydrophobic drugs.